Exome sequencing in bipolar disorder identifies AKAP11 as a risk gene shared with schizophrenia

DSpace/Manakin Repository

Exome sequencing in bipolar disorder identifies AKAP11 as a risk gene shared with schizophrenia
 
Palmer, Duncan S; Howrigan, Daniel P; Chapman, Sinéad B; Adolfsson, Rolf; Bass, Nick; Blackwood, Douglas; Boks, Marco P M; Chen, Chia-Yen; Churchhouse, Claire; Corvin, Aiden P; Craddock, Nicholas; Curtis, David; Di Florio, Arianna; Dickerson, Faith; Freimer, Nelson B; Goes, Fernando S; Jia, Xiaoming; Jones, Ian; Jones, Lisa; Jonsson, Lina; Kahn, Rene S; Landén, Mikael; Locke, Adam E; McIntosh, Andrew M; McQuillin, Andrew; Morris, Derek W; O'Donovan, Michael C; Ophoff, Roel A; Owen, Michael J; Pedersen, Nancy L; Posthuma, Danielle; Reif, Andreas; Risch, Neil; Schaefer, Catherine; Scott, Laura; Singh, Tarjinder; Smoller, Jordan W; Solomonson, Matthew; Clair, David St; Stahl, Eli A; Vreeker, Annabel; Walters, James T R; Wang, Weiqing; Watts, Nicholas A; Yolken, Robert; Zandi, Peter P; Neale, Benjamin M
(2022) Nature Genetics, volume 54, issue 5, pp. 541 - 547
(Article)
Abstract
We report results from the Bipolar Exome (BipEx) collaboration analysis of whole-exome sequencing of 13,933 patients with bipolar disorder (BD) matched with 14,422 controls. We find an excess of ultra-rare protein-truncating variants (PTVs) in patients with BD among genes under strong evolutionary constraint in both major BD subtypes. We find ... read more
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Genetics, Journal Article
DOI: https://doi.org/10.1038/s41588-022-01034-x
ISSN: 1061-4036
Publisher: Nature Research
Note: Funding Information: This study was supported by the Stanley Family Foundation; Kent and Elizabeth Dauten; National Institutes of Health grants R01 CA194393 (B.M.N.), R37 MH107649 (B.M.N.) and R01 MH085542 (J.W.S.); National Institute of Mental Health grants R01 MH090553 (R.O.), R01 MH095034 (E.A.S.) and U01 MH105578 (N.B.F.); UK Medical Research Council grants G1000708 (A.M.), MR/L010305/1 (M.J.O.) and MR/P005748/1 (M.J.O., M.C.O. and J.W.); ongoing grant support from Stanley Medical Research Institute (F.D., and R.Y.); and The Dalio Foundation (B.M.N.), who have enabled us to rapidly expand our data generation collections with the goal of moving toward better treatments for BD, schizophrenia and other psychiatric disorders. BSC grant support was provided by the National Institutes of Health grants R01 MH110437 (P.Z.), R01 MH085543 (C.S.) and RC2 AG036607 (C.S. and N.R.). We thank W. Ouwehand for contributing control samples for exome sequencing and E. Wigdor for thoughtful comments. Funding Information: This study was supported by the Stanley Family Foundation; Kent and Elizabeth Dauten; National Institutes of Health grants R01 CA194393 (B.M.N.), R37 MH107649 (B.M.N.) and R01 MH085542 (J.W.S.); National Institute of Mental Health grants R01 MH090553 (R.O.), R01 MH095034 (E.A.S.) and U01 MH105578 (N.B.F.); UK Medical Research Council grants G1000708 (A.M.), MR/L010305/1 (M.J.O.) and MR/P005748/1 (M.J.O., M.C.O. and J.W.); ongoing grant support from Stanley Medical Research Institute (F.D., and R.Y.); and The Dalio Foundation (B.M.N.), who have enabled us to rapidly expand our data generation collections with the goal of moving toward better treatments for BD, schizophrenia and other psychiatric disorders. BSC grant support was provided by the National Institutes of Health grants R01 MH110437 (P.Z.), R01 MH085543 (C.S.) and RC2 AG036607 (C.S. and N.R.). We thank W. Ouwehand for contributing control samples for exome sequencing and E. Wigdor for thoughtful comments. Funding Information: B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora and a consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. A.M.M. has received speaker fees from Illumina and Janssen and research grant support from The Sackler Trust. M.L. has received speakers fees from Lundbeck Pharmaceuticals. M.J.O., M.C.O. and J.W. have received a research grant from Takeda Pharmaceuticals outside the scope of the present study. F.S.G. has received a research grant from Janssen Pharmaceuticals outside the scope of the present study. C.-Y.C. is an employee of Biogen. F.D. is an employee of Sheppard Pratt. A.E.L. and E.A.S. are now employees of Regeneron. X.J. is now an employee of Genentech. All other authors declare no competing interests. Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.
(Peer reviewed)